Your browser doesn't support javascript.
loading
Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase.
Yao, Hang-Ping; Tong, Xiang-Min; Wang, Ming-Hai.
Afiliação
  • Yao HP; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: yaohangping@zju.edu.cn.
  • Tong XM; Department of Hematology, Zhejiang Provincial People's Hospital and People's Hospital of Hangzhou Medical College, Hangzhou, China.
  • Wang MH; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Biology Research Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA; Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University He
Drug Discov Today ; 26(1): 106-121, 2021 01.
Article em En | MEDLINE | ID: mdl-33171292
ABSTRACT
Pharmaceutical innovation in the development of novel antibody-based biotherapeutics with increased therapeutic indexes makes MET-targeted cancer therapy a clinical reality.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biofarmácia / Proteínas Proto-Oncogênicas c-met / Antineoplásicos Imunológicos / Neoplasias Limite: Humans Idioma: En Revista: Drug Discov Today Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biofarmácia / Proteínas Proto-Oncogênicas c-met / Antineoplásicos Imunológicos / Neoplasias Limite: Humans Idioma: En Revista: Drug Discov Today Ano de publicação: 2021 Tipo de documento: Article